Comparison of $^{90}$Y SIRT predicted and delivered absorbed doses using a PSF conversion method

Allison J. Craig $^{a,b,*}$, Iain Murray $^{a,b}$, Ana M. Denis-Bacelar $^c$, Bruno Rojas $^{a,b}$, Jonathan I. Gear $^{a,b}$, Lucy Hossen $^a$, Annelies Maenhout $^a$, Nasir Khan $^c$, Glenn D. Flux $^{a,b}$

$^a$ Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom
$^b$ The Institute of Cancer Research, London, United Kingdom
$^c$ National Physical Laboratory, Teddington, United Kingdom

A B S T R A C T

Purpose: The aims of this study were to develop and apply a method to correct for the differences in partial volume effects of pre-therapy Technetium-99 m ($^{99m}$Tc)-MAA SPECT and post-therapy Yttrium-90 ($^{90}$Y) bremsstrahlung SPECT imaging in selective internal radiation therapy, and to use this method to improve quantitative comparison of predicted and delivered $^{90}$Y absorbed doses.

Methods: The spatial resolution of $^{99m}$Tc SPECT data was converted to that of $^{90}$Y SPECT data using a function calculated from $^{99m}$Tc and $^{90}$Y point spread functions. This resolution conversion method (RCM) was first applied to $^{99m}$Tc and $^{90}$Y SPECT phantom data to validate the method, and then to clinical data to assess the power of $^{99m}$Tc SPECT imaging to predict the therapeutic absorbed dose.

Results: The maximum difference between absorbed doses to phantom spheres was 178%. This was reduced to 27% after the RCM was applied. The clinical data demonstrated differences within 38% for mean absorbed doses delivered to the normal liver, which were reduced to 20% after application of the RCM. Analysis of clinical data showed that therapeutic absorbed doses delivered to tumours greater than 100 cm$^3$ were predicted to within 52%, although there were differences of up to 210% for smaller tumours, even after the RCM was applied.

Conclusions: The RCM was successfully verified using phantom data. Analysis of the clinical data established that the $^{99m}$Tc pre-therapy imaging was predictive of the $^{90}$Y absorbed dose to the normal liver to within 20%, but had poor predictability for tumours smaller than 100 cm$^3$.

Keywords: Radioembolisation, Y-90, SIRT, Liver, Dosimetry, Microspheres

Introduction

Selective internal radiation therapy (SIRT) is used to treat Hepato-cellular Carcinoma and liver metastases originating from other primary cancers. Yttrium-90 ($^{90}$Y) microspheres are administered via a catheter directly into the hepatic artery where they are deposited within the hepatic arterioles surrounding the tumours. Pre-therapy imaging with Technetium-99 m ($^{99m}$Tc) labelled macroaggregated albumin (MAA) is performed to assess any extra-hepatic uptake. This includes calculation of the lung shunt, a measure of the microsphere deposition within the lungs. Post-therapy imaging may be performed by $^{90}$Y PET or bremsstrahlung SPECT. $^{90}$Y PET has been shown to be more quantitatively accurate than bremsstrahlung SPECT [1,2]. However, SPECT is more widely available and cost-effective [3]. Quantitative $^{90}$Y bremsstrahlung SPECT imaging is challenging due to the lack of a photopeak. It also has poor spatial resolution compared to $^{99m}$Tc SPECT imaging, with large tails in the $^{90}$Y point spread function (PSF) due to high energy bremsstrahlung photons penetrating the collimator septa [4]. Despite this $^{90}$Y bremsstrahlung imaging has been used for over 35 years for both planar and SPECT quantification [5–11]. $^{90}$Y activity calculations and treatment planning may be based on the pre-therapy $^{99m}$Tc-MAA SPECT imaging, and rely on the assumption that the MAA particle distribution is identical to that of the $^{90}$Y-microsphere distribution. However, there are a number of reasons why this
assumption may be flawed which include differences in the size and number of particles administered [12], the catheter position [13–15], administration flow rates [13–15] and regional blood flow differences taking between administrations [16]. Previous studies have compared the pre- and post-therapy imaging [14,17–19], with the majority of these studies taking no account of the differences in the partial volume effect of the images [14,17–19]. However, Gnesin et al [20] applied recovery coefficients to predicted and delivered absorbed doses to tumours derived from $^{99m}$Tc-MAA SPECT and $^{90}$Y PET images respectively, while a recent study by Mikkeli et al [21] convolved $^{90}$Y PET images with a Gaussian function to match the spatial resolution of $^{99m}$Tc-MAA SPECT images.

The aim of this study was to develop a resolution conversion method (RCM) to correct for the differences in partial volume effects between $^{99m}$Tc-MAA SPECT and $^{90}$Y bremsstrahlung SPECT images. The RCM converts the spatial resolution of the $^{99m}$Tc SPECT data to that of a post-therapy $^{90}$Y SPECT image by convolution with a function calculated from $^{99m}$Tc and $^{90}$Y point spread functions. This method was then applied retrospectively to patient data to assess the ability of quantitative $^{99m}$Tc-MAA SPECT to predict $^{90}$Y normal liver and tumour absorbed doses.

Methods

Resolution conversion method

A method, named the resolution conversion method (RCM), was developed to convert a reconstructed $^{99m}$Tc-MAA SPECT image, $I_{99m}$, to the same spatial resolution as a reconstructed $^{90}$Y bremsstrahlung SPECT image. The RCM operates by the convolution of the $^{99m}$Tc reconstructed SPECT data with a function ($P_{99m}$) calculated from the measured $^{99m}$Tc and $^{90}$Y PSF’s $I_{99m}$ and $P_{90}$, respectively. $P_{99m}$ is defined such that:

$$P_{99m} = p_{99m} \otimes p_{90}$$  \hspace{1cm} (1)

$p_{99m}$ is described as a Gaussian function with a standard deviation $\sigma_{99m}$:

$$p_{99m} = \frac{1}{(2\pi)^{3/2} \sigma_{99m}} e^{-[r^2/2\sigma_{99m}^2]}$$  \hspace{1cm} (2)

where

$$r^2 = x^2 + y^2 + z^2$$  \hspace{1cm} (3)

and

$$\int_{-\infty}^{\infty} \int_{-\infty}^{\infty} \int_{-\infty}^{\infty} p_{99m} \, dx \, dy \, dz = 1$$  \hspace{1cm} (4)

where

$$dr = dx \, dy \, dz.$$  \hspace{1cm} (5)

The measured FWHM values were all shown to be within one voxel, thus $\sigma_{99m}$ is assumed to be the same in the x, y and z directions.

$p_{90}$ cannot be adequately described by using a single Gaussian function due to the presence of large septal penetration tails [4]. Therefore $P_{90}$ is described by the sum of two Gaussian functions ($P_{901}$ and $P_{902}$):

$$P_{90} = P_{901} + P_{902}$$  \hspace{1cm} (6)

where $P_{901}$ and $P_{902}$ are two independent functions given by:

$$P_{901} = \frac{A_1}{(2\pi)^{3/2} \sigma_{901}^2} e^{-[r^2/2\sigma_{901}^2]}$$  \hspace{1cm} (7)

$$P_{902} = \frac{A_2}{(2\pi)^{3/2} \sigma_{902}^2} e^{-[r^2/2\sigma_{902}^2]}$$  \hspace{1cm} (8)

$\sigma_{901}$ and $\sigma_{902}$ are the standard deviations describing the respective Gaussian distribution functions, and $A_1$ and $A_2$ are constants derived from the integrals of the Gaussian distributions under the constraint that:

$$\int_{-\infty}^{\infty} \int_{-\infty}^{\infty} \int_{-\infty}^{\infty} p_{901} \, dx \, dy \, dz = \int_{-\infty}^{\infty} \int_{-\infty}^{\infty} \int_{-\infty}^{\infty} p_{902} \, dx \, dy \, dz = 1$$

$$\int_{-\infty}^{\infty} \int_{-\infty}^{\infty} \int_{-\infty}^{\infty} p_{90} \, dx \, dy \, dz = 1$$

As $p_{90}$ consists of two independent functions, the same must be true for $P_{901}$ and $P_{902}$, and each of these can be convolved separately with $p_{99m}$. Therefore, $P_{99m} \otimes P_{901}$ may be expressed as:

$$p_{99m} \otimes P_{901} = P_{99m} \otimes P_{902}$$

where

$$P_{99m} \otimes P_{901} = \frac{B_1}{(2\pi)^{3/2} \sigma_{99m}^2} e^{-[r^2/2\sigma_{99m}^2]}$$

and

$$P_{99m} \otimes P_{902} = \frac{B_2}{(2\pi)^{3/2} \sigma_{99m}^2} e^{-[r^2/2\sigma_{99m}^2]}$$

with standard deviations $\sigma_{99m}$ and $\sigma_{99m}$. $P_{99m}$ and $\sigma_{99m}$ and each of these can be convolved separately with $p_{99m}$. Therefore, $P_{99m}$ may be expressed as:

$$P_{99m} = p_{99m} \otimes p_{90}$$

where

$$P_{99m} = \frac{B_1}{(2\pi)^{3/2} \sigma_{99m}^2} e^{-[r^2/2\sigma_{99m}^2]}$$

and

$$P_{99m} = \frac{B_2}{(2\pi)^{3/2} \sigma_{99m}^2} e^{-[r^2/2\sigma_{99m}^2]}$$

The convolution of a Gaussian function with another Gaussian function results in a third Gaussian function with a variance equal to the sum of the variances in the original two functions [22]. The variances $\sigma_{99m}$ and $\sigma_{99m}$ are then given by:

$$\sigma_{99m}^2 = \sigma_{99m}^2 + \sigma_{99m}^2$$

and

$$\sigma_{99m}^2 = \sigma_{99m}^2 + \sigma_{99m}^2$$

Thus the variances of $P_{99m}$ are defined as:

$$\sigma_{99m}^2 = \sigma_{99m}^2 - \sigma_{99m}^2$$

and

$$\sigma_{99m}^2 = \sigma_{99m}^2 - \sigma_{99m}^2$$

Thus the convolution of the $^{99m}$Tc SPECT image, $I_{99m}$, to a representation of an image with a $^{90}$Y resolution, $I_{90m}$, is given by:

$$I_{99m} \otimes P_{90} = \frac{B_1}{(2\pi)^{3/2} \sigma_{99m}^2} e^{-[r^2/2\sigma_{99m}^2]} + I_{99m} \otimes P_{90}$$

Measurement of the point spread functions

A point source of $^{99m}$Tc was placed into the NEMA IEC phantom and a SPECT-CT acquisition was performed on a Siemens Symbia SPECT-CT system (Siemens Healthcare Limited, Erlangen, Germany), with the source centred in the x-y plane. The acquisition was then repeated with a point source of $^{90}$Y. SPECT acquisition parameters are detailed in Table 1. Non-circular orbits were performed for all scans to match with the standard clinical protocol.

Reconstruction parameters

$^{99m}$Tc SPECT acquisition data were reconstructed using an OSEM
algorithm for 5 iterations, 8 subsets, CT attenuation correction and scatter correction (Hermes Medical Solutions, Hybrid Viewer). $^{99m}$Tc SPECT acquisition data were reconstructed for 5 iterations, 8 subsets and CT attenuation correction was performed for 95 keV, the mid-point of the $^{99m}$Tc energy window.

Analysis of point spread function measurements

Profiles were drawn through the reconstructed image of the $^{99m}$Tc point source in three orthogonal planes (x, y, z) to obtain the PSF. Full width half maximum (FWHM) values were calculated for each plane using the method described by NEMA [23]. An average FWHM was used to calculate $\sigma_{FWMH}$ for input into equations 17 and 18.

Voxel count values and positions were extracted from the reconstructed $^{99m}$Tc SPECT image from a cubic volume of interest (23 cm$^3$) centred on the point source. A mathematical model, which consisted of the sum of two Gaussian functions (equations 6–8), was fitted to these data, using a method of least squares (Solver, Microsoft Excel (2010)) which iteratively minimises the sum of the square of the residuals between the fitted and measured data. Values of the fit parameters $\sigma_{FWMH}$ and $\sigma_{Y}$ were input into equations 17 and 18.

Phantom study

Phantom SPECT scans

A phantom study was undertaken to validate the RCM. The NEMA IEC phantom, with six spherical inserts of diameter: 37, 28, 22, 17, 13 and 10 mm, was filled with radioactivity to represent the normal liver background, whilst the spheres were filled with higher activities to represent tumours. Four clinically realistic sphere-to-background ratios ranging from 50 to 168 MBq for $^{99m}$Tc and $^{90}$Y SPECT data with the calculation of the percentage differences (%$\Delta D$) between them according to:

$$\%\Delta D = \frac{D_{99mTc} - D_{90Y}}{D_{90Y}} \times 100$$

where $D_{99mTc}$ is the mean $^{99m}$Tc absorbed dose derived from the $^{99m}$Tc SPECT and $D_{90Y}$ is the mean $^{90}$Y absorbed dose derived from the $^{90}$Y SPECT. The percentage difference in absorbed doses derived from the $^{99m}$Tc SPECT after the application of the RCM and the $^{90}$Y SPECT were also calculated:

$$\%\Delta D = \frac{D_{99mTc/RCM} - D_{90Y}}{D_{90Y}} \times 100$$

where $D_{99mTc/RCM}$ is the mean $^{99m}$Tc absorbed dose derived from the RCM $^{99m}$Tc SPECT image.

Uncertainties in the absorbed dose comparisons were calculated using the law of propagation of uncertainty described within the Bureau International des Poids et Mesures (BIPM) Guide to expression of uncertainty in measurement [27] and detailed by Gear et al [28].

Clinical study

Patient characteristics

The RCM was applied to SPECT-CT data in a retrospective study of 16 patients who had undergone $^{90}$Y resin microsphere treatment. All patients had a contrast enhanced CT (CECT) scan between 12 and 141 days prior to treatment, and no other liver treatments were performed between the CECT and SIRT. The patients had a range of primary tumour sites (colorectal, oesophago-gastric junction, breast, pancreatic and cholangiocarcinoma) with tumour burden ranging from 1% to 44%.
Administered $^{90}$Y activity ranged from 900 to 2320 MBq.

**Planning and administration of SIRT**

All patients were treated following pre-therapy angiography to evaluate the hepatic vasculature and to identify and embolise any aberrant vessels that may have led to extra-hepatic uptake of the microspheres. $^{99m}$Tc-MAA was administered and planar imaging performed to assess the lung shunt, followed by SPECT-CT imaging. The $^{90}$Y resin microsphere activity was calculated using the body surface area (BSA) method:

$$A_0 = (\text{BSA} - 0.2) + \left( \frac{V_{\text{tumour}}}{V_{\text{tumour}} + V_{\text{normal liver}}} \right)$$

where $V_{\text{tumour}}$ is the volume of the tumour and $V_{\text{normal liver}}$ is the volume of the normal liver. Both parameters were determined by manual delineation of the liver and tumours on the diagnostic CECT scan. The BSA was calculated using the DuBois and DuBois method [29].

The administration of the $^{90}$Y microspheres was performed by slow infusion, and $^{90}$Y bremsstrahlung SPECT-CT imaging was performed directly after treatment (Table 1). Acquisition data were reconstructed using the same reconstruction parameters as for the phantom study.

**Absorbed dose calculation**

The RCM was applied to the $^{99m}$Tc SPECT patient images. Reconstructed SPECT data were registered to the CECT scans using automatic rigid registration in Hermes Hybrid Viewer, followed by manual adjustment if necessary. Liver and tumour VOIs were manually delineated on the CECT. Tumours below 2.6 cm$^3$ and those with no uptake on the pre-therapy scan were excluded. $^{90}$Y absorbed dose maps were calculated from the uncorrected $^{99m}$Tc, RCM $^{99m}$Tc, and $^{90}$Y SPECT images, as described in equation 21, using a patient-specific calibration factor (equation 22) where the total counts were obtained from the liver.

---

**Fig. 1.** A) example of $^{99m}$Tc PSF with a Gaussian function fitted to it and B) example of $^{90}$Y PSF with the sum of two Gaussian functions fitted to it.
VOI.

Analysis

The tumour and liver VOIs were transcribed to the absorbed dose maps and manually adjusted if any clear mis-registration was visible. Mean absorbed doses to the tumours and normal liver were calculated, and voxel dose values within the normal healthy liver were used to calculate dose volume histogram (DVH) metrics: $D_{50}$ (minimum absorbed dose value received by 50% of the normal liver) and $D_{70}$ (minimum absorbed dose value received by 70% of the normal liver). The percentage differences in mean absorbed doses, $D_{50}$ and $D_{70}$, derived from predicted and delivered absorbed dose maps were calculated as previously defined (equations 23 and 24). Bland-Altman analysis was also performed. Percentage differences were also plotted as a function of tumour size. Uncertainties in the absorbed dose comparisons were calculated as for the phantom calculations.

Results

Measurement of point spread functions

The $x$, $y$ and $z$ FWHM values for $^{99m}$Tc were 9.8, 12.7 and 12.2 mm respectively. An average value of 11.6 mm was calculated with a standard deviation $\sigma_{99mTc} = 4.9$ mm. An example of a $^{99m}$Tc PSF with a Gaussian function fitted to it can be seen in Fig. 1a.

The sum of two Gaussian functions was fitted to the 3-dimensional $^{90}$Y PSF ($p_{Y90}$) which resulted in FWHM values of 19.2 mm ($p_{Y901}$) and 86.4 mm ($p_{Y902}$). This gave standard deviations $\sigma_{Y901} = 8.2$ mm and $\sigma_{Y902} = 36.7$ mm, with $A_1 = 0.34$ and $A_2 = 0.66$. An example of a $^{90}$Y PSF with the sum of two Gaussian functions fitted to it can be seen in Fig. 1b.

The standard deviations of the function ($p_{99mTc\rightarrow Y90}$) used in the RCM were then calculated from equations 17 and 18 as $\sigma_{99mTc\rightarrow Y901} = 6.5$ mm and $\sigma_{99mTc\rightarrow Y902} = 36.4$ mm.

Phantom study

Phantom background

Comparison between the absorbed doses to the phantom background, calculated from the $^{99m}$Tc and $^{90}$Y SPECT scans, gave a range of differences from $0.5\%$ to $3.6\%$. After the application of the RCM the range of differences was $0.1\%$ to $3.3\%$.

Phantom spheres

The mean absorbed dose to each of the three smallest spheres (all less than $2.6\,cm^3$) was less than one standard deviation above the mean absorbed dose delivered to the background compartment for all four of the $^{90}$Y phantom SPECT scans, rendering them undetectable. Therefore these were excluded from the analysis.

A wide range of differences ($0$ to $178\%$) between sphere absorbed doses derived from $^{99m}$Tc and $^{90}$Y SPECT data was obtained, (Fig. 2). After the application of the RCM the differences ranged from $-15\%$ to...

Fig. 2. Percentage difference of predicted and delivered $^{90}$Y absorbed doses to the phantom spheres A) before and B) after application of the RCM. The different shades represent the different sphere-to-background ratios.
Clinical study

Normal liver

The range of percentage differences between predicted and delivered absorbed doses were −38% (9 Gy) to 3% (1 Gy) (Fig. 3). Bland-Altman analysis is given in Fig. 4 where a bias of −17% was calculated. After the application of the RCM the percentage differences between the predicted and delivered mean absorbed doses were reduced to a range of −20% (5 Gy) to 4% (1 Gy) (Fig. 3) and a bias of −10% was found.

The percentage differences between the predicted and delivered D50 values ranged from −75% to −10%, and decreased to −31% to 4% after the application of the RCM. The percentage differences between the predicted and delivered D70 ranged from −91% to −33%, and decreased to −43% to 11% after the application of the RCM. Graphs can be seen in the supplemental material.

Tumours

Seventy-four tumours were analysed in total with a range in volume of 2.7 cm³ to 763.6 cm³ (equivalent diameters of 17.2 mm to 113.4 mm). The percentage differences between predicted and delivered absorbed doses to the tumours ranged from −49% (36 Gy) to 424% (205 Gy) (Fig. 5). The maximum absolute difference in absorbed dose was 216 Gy (195%).

After application of the RCM the percentage differences of the tumour absorbed doses ranged from −55% (41 Gy) to 210% (59 Gy) (Fig. 5). The maximum absolute difference in absorbed doses to the tumours was 78 Gy (161%). No correlation was found between the percentage difference and the number of days between the CECT and the SIRT (r = 0.09, p = 0.5). Examples of pre- and post-therapy SPECT-CT scans with good and poor agreement are included in the supplemental material.

Bland-Altman analysis (Fig. 6) demonstrated no relationship between the mean absorbed doses to the tumours and the percentage differences. A bias of 90% was found, which indicates that the predicted absorbed doses to the tumours were higher than the delivered absorbed doses. This was reduced to 34% after the RCM was applied.

A larger range of percentage differences in tumour absorbed doses was demonstrated for smaller tumours than for larger tumours (Fig. 7). The range of percentage differences for tumours less than 100 cm³ (equivalent diameter 57.6 mm) was −49% to 424% before, and −55% to 210% after the RCM was applied. This was −23% to 67% before and −30% to 52% after the application of the RCM, for tumours greater than 100 cm³.

Discussion

SIRT has been shown to be a successful treatment demonstrating good tumour response [30–32] and increasing time to further hepatic progression [32–35]. Prospective treatment planning with pre-therapy 99mTc-MAA SPECT has demonstrated a good correlation between tumour dose and response [35–37]. However, studies have shown contrasting findings when investigating the predictive power of the pre-therapy 99mTc-MAA distribution [16,17,19,20,38–40]. To allow direct quantitative comparison between predicted and delivered 90Y absorbed dose, a novel RCM method was developed to address the differences in partial volume effects between 99mTc-MAA SPECT and 90Y brachytherapy SPECT images by converting the spatial resolution of the pre-therapy scan data to that of the post-therapy scan data. The method was validated on phantom scans and then applied retrospectively to a set of patient data. A similar method has also been proposed by Mikell et al. [21] who blurred the 90Y PET to match the 99mTc SPECT.

Point spread functions for 99mTc and 90Y SPECT were measured experimentally and used as inputs into the RCM. The 90Y PSF was fitted to a mathematical model of the sum of two Gaussian functions to incorporate the large septal penetration tails. The PSF’s for 131I [41] and 123I [42] have previously been fitted with a Gaussian and an exponential function to account for septal penetration tails in the collimator detector response compensation.

The phantom study validated the use of the RCM and established differences between predicted and delivered 90Y absorbed doses due to measurement uncertainties. Deviations observed in the clinical analysis were considered due to either biological differences in the particle distributions between the pre- and post-clinical scans caused by differences in particle size or catheter positioning, or due to limitations of the phantom study. Regions within the phantom only allowed for uniform activity distributions. In addition, the individual sphere volumes, and the total sphere volume, were small compared to many of the tumours identified in the clinical study. Comparison of the predicted and delivered 90Y absorbed doses demonstrated small differences before and after the application of the RCM for the phantom background. Analysis of the mean absorbed doses in the phantom spheres identified large differences of up to 178%; these were reduced to 27% with the application of the RCM.

Analysis of the patient data demonstrated the predictive power of the
$99m\text{Tc}$-MAA pre-therapy imaging, with differences between predicted and delivered mean absorbed dose to the normal liver reduced from 38% to less than 20% after the application of the RCM. This is larger than the differences demonstrated in the validation for the phantom background and could be due to either the limitations of the phantom, biological differences in the particle distributions or due to tumoural uptake from the SPECT scan included within the normal liver VOIs. The DVH metrics demonstrated less agreement than the mean absorbed dose; they were

Fig. 4. Bland-Altman analysis of predicted versus delivered absorbed doses to normal liver A) before and B) after application of the RCM. The bias shown by the solid line was $-17\%$, reduced to $-10\%$ after the application of the RCM. The 95% confidence intervals are represented by the dashed lines.

Fig. 5. Histograms of the percentage difference between predicted and delivered absorbed dose to the tumours A) before and B) after application of the RCM.

Fig. 6. Bland-Altman analysis of predicted versus delivered absorbed doses to tumours A) before and B) after application of the RCM. The bias was shown by the solid line as $90\%$, reduced to $34\%$ after the application of the RCM. The 95% confidence intervals are represented by the dashed lines.
A) Percentage difference in mean absorbed dose to the tumours [%] application of the RCM. Once was 271%, and 115% after the RCM was applied. B) Percentage difference in mean absorbed dose to the normal liver within 20%. A previous comparison demonstrated good concordance between predicted and delivered absorbed doses, although absolute and percentage differences were not reported.

The application of the RCM resulted in a reduction of both the percentage and absolute differences between the predicted and delivered absorbed doses to the tumours, as well as a reduction in the bias from 90% to 34%. However, a wide range of differences were still present after the RCM was applied. In this study 41% of tumours (after application of the RCM) had an absorbed dose difference above 50%. This is in agreement with Willouson et al [38] who found that 40% of tumours demonstrated a difference between predicted and delivered absorbed dose of more than 50%. No significant differences in tumour absorbed dose were found by Kafrouni et al [39], although values for specific tumours were not detailed. A large variation in absorbed dose differences was found for tumours less than 100 cm³ (equivalent diameter 57.6 mm). This is in agreement with Gnesin et al [20] who also demonstrated large variability for tumours less than 150 cm² with an over-estimation in the predicted absorbed dose. It is not clear why there is such a large variation for small tumours even after accounting for differences in the partial volume effect with the application of the RCM. However, small tumours are often not clearly visible on the 99mTc SPECT scans. This could result in greater misregistration errors and in turn lead to larger errors on the absorbed doses. The embolic effect of the resin microspheres may be more pronounced for smaller tumours with less vasculature surrounding them, resulting in different MAA and microsphere distributions. This hypothesis is supported by a previous study where glass microspheres were used preferentially over resin microspheres for small tumours to prevent tumour saturation and reflux into the normal liver [20]. It is also worth noting that the RCM method results in a degradation of the 99mTc SPECT image, thus for small tumours with low intensity the signal may be lost.

There are some limitations to this study. It is well known that the PSF varies across the field of view [43]; in this work one PSF was used for the whole field of view. This could lead to uncertainties in the application of the RCM as demonstrated by comparison of the absorbed doses to the spheres where differences of up to 27% were observed. 99mTc bremssstrahlung imaging is challenging, and in this work scatter and collimator detector response corrections were not performed during 99mTc reconstruction which will limit the quantitative accuracy [2,3]. It is possible that there was some degree of misregistration between the clinical SPECT and CECT scans. The time gap between these scans could result in changes to the tumour liver anatomy between scans. Patient positioning for the CECT, 99mTc SPECT and 99mTc SPECT scans could also be different, leading to further misregistration which will result in the CECT VOIs being incorrectly placed on the SPECT scans and could lead to larger errors for smaller tumours. To minimise these errors, SPECT scans were manually adjusted after automatic registration. The position of VOIs was also manually adjusted if a clear mismatch was visible. Delineation was performed on the CECT scan. This method was chosen specifically to ensure analysis of identical tumour and normal liver areas between the pre-and post-therapy SPECT scans. However, it is accepted that this may have led to large differences in the comparison of the uncorrected SPECT scans due to different spatial resolutions. An alternative method would have been to use a thresholding method to define the VOIs. However, this method comes with its own disadvantages. The use of threshold VOIs is challenging with the optimal VOI choice dependant on tumour size as well as tumour to normal liver contrast. The advantage of the RCM is that it can be applied globally to a heterogeneous distribution of tumours. The PSFs fitted in this study are acquisition and reconstruction parameter dependent, therefore reproduction of this work would involve centres undertaking their own measurements.

Conclusions

A resolution conversion method (RCM) was developed to overcome the differences in partial volume effects between predicted and delivered absorbed dose distributions. After initial validation with phantom data this was applied retrospectively to patient data. The analysis of this clinical data demonstrated that the RCM reduced the differences in the mean absorbed dose to the normal liver and led to the conclusion that the 99mTc pre-therapy imaging was predictive of the 99mTc mean absorbed dose to the normal liver to within 20%. However, although a reduction in the differences between the predicted and delivered mean absorbed doses to tumours was seen after the application of the RCM, the 99mTc pre-therapy imaging had poor predictability for tumours smaller than 100 cm³.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study utilised anonymised patient data collected as standard routine protocol only, and as such ethics committee approval was not required. All patients gave written informed consent.
Appendix A. Supplementary data

the NHS, the NIHR or the Department of Health and Social Care. Views expressed are those of the author(s) and not necessarily those of the Department for Business, Energy and Industrial Strategy.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We acknowledge additional NHS funding to the NIHR Biomedical Research Centre and Clinical Research Facility in Imaging at The Royal Marsden and Institute of Cancer Research and the Radiotherapy Trials Quality Assurance Group. This work was supported by the UK’s National Measurement System (NMS) programme of the Government’s Department for Business, Energy and Industrial Strategy.

Disclaimer

This paper presents independent research funded by the National Institute for Health Research (NIHR) and Health Education England. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ejmp.2021.07.026.

References

[1] Salem R, Padia SA, Lam M, Bell J, Chiesa C, Fowers K, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46(7):1695–704.

[2] Elchot M, Vermolen BJ, Lam MGEH, de Keizer B, van den Bosch MAAJ, de Jong HWAM, et al. Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS ONE 2015;10(8):e0135742. https://doi.org/10.1371/journal.pone.0055742.

[3] Dewaraja YK, Chun SY, Srivinasa RN, Kaza RK, Cuneo KC, Majdalany BS, et al. Improved quantitative Y90 bremsstrahlung SPECT/CT reconstruction with Monte Carlo scatter modeling. Med Phys. 2017;44(12):6364–76.

[4] Elchot M, Nijsen JFW, Dam AJ, de Jong HWAM, Boswell CA. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS ONE 2011;6(11):e26174. https://doi.org/10.1371/journal.pone.0026174.

[5] Ott RJ, Flower MA, Jones A, McCready VR. The measurement of radiation doses from P32 chronic phosphorus therapy of the peritonium using SPECT. Eur J Nucl Med. 1985;11(4):305–8.

[6] Siegel JA, Handy DM, Kopfar KA, Zeiger LS, Order SE. Therapeutic Beta-Irradiating Isotopes in Bone Metastasis - a Technique for Bremsstrahlung Imaging and Quantitation. Antibody Immunoncon. 1992;5(3):237–46.

[7] Clarke LP, Gullom SJ, Shave RC, Fenney BC, King MA, et al. Bremsstrahlung Imaging Using the Gamma Camera - Factors Affecting Attenuation. J Nucl Med. 1992;33(1):161–6.

[8] Shen S, DeNardo GL, Yuan A, DeNardo DA, DeNardo SJ. Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med. 1994;35(8):1381–9.

[9] Siegel JA. Quantitative Bremsstrahlung SPECT Imaging - Attenuation-Corrected Activity Determination. J Nucl Med. 1994;35(7):1213–6.

[10] Siegel JA, Zeiger LS, Order SE, Wallner PE. Quantitative Bremsstrahlung Single-Photon Emission Computed Tomographic Imaging - Use for Volume, Activity, and Absorbed Dose Calculations. Int J Radiat Oncol. 1995;31(4):953–8.

[11] Ito S, Kurosawa H, Kasahara H, Terasaka S, Arita E, Dej J, et al. Y-90 bremsstrahlung emission computed tomography using gamma cameras. Ann Nucl Med 2009;23(3):257–67.

[12] Chiesa C, Maccario M, Romito S, Spreafico C, Pellizzari S, Negri A, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with Y-90 microspheres: the experience of the National Cancer Institute of Milan. Q J Nucl Med Mol Imaging. 2012;56(2):168–97.

[13] Jiang ML, Fuchsan A, Nowakowski S, Heiba S, Zhang Z, Kneseruek K, et al. Segmental Perfusion Differences on Paired To-99m Microaggregated Albumin (MAA) Hepatic Perfusion Imaging and Yttrium-90 (Y-90) Bremsstrahlung Imaging in Studies in SIR-Sphere Radioembolization: Associations with Angiography. Journal of Nuclear Medicine & Radiation. Therapy. 2012;3(11).

[14] Wondergem M, Smits MLI, Elchot M, de Jong HWAM, Verkooijen HM, van den Bosch MAAJ, et al. 90Y-Microaggregated Albumin Poorly Predicts the Intrahepatic Distribution of 90Y Resin Microspheres in HEPatic Radioembolization. J Nucl Med. 2013;54(4):1294–301.

[15] Kennedy A, Nag S, Salem R, Murphy R, McWan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. Int J Radiat Oncol. 2007;68(3):121–33.

[16] Cremoneosi M, Chiesa C, Brigitt L, Ferrari M, Botta F, Guerrieri P, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol 2014;4. https://doi.org/10.3389/fonc.2014.00210.

[17] Kneseruek K, Machac J, Muzinaite M, DaCosta M, Zhang ZY, Heiba S, Qualitative Comparison of Yttrium-90 (Y-90)-Microspheres and Technetium-99m-MAA-Microaggregated Albumin SPECT Images for Planning Y-90 Therapy of Liver Cancer. Technol Cancer Res T. 2010;9(3):253–61.

[18] Illhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Todica AS, et al. Predictive value of 99mTc-labelled MAA scintigraphy for 90Y-microspheres in radioembolization treatment with resin microspheres in secondary hepatic tumors in humans. J Nucl Med. 2015;56(11):1654–60.

[19] Debebe SA, Adjouadi M, Gulec SA, Franquiz J, McGoron AJ. The activity distribution in radioembolization treatment with resin microspheres in primary and secondary hepatic malignancies. J Nucl Med. 2015;56(11):1654–60.

[20] Mikell JK, Majdalany BS, Owen D, Paradis KC, Dewaraja YK. Assessing Spatial Concordance Between Theranostic Pairs Using Phantom and Patient-Specific Acceptance Criteria: Application to (99mTc)MAA SPECT/CT. J Nucl Med. 2019;20(2):30–42.

[21] Gniesz S, Canetti L, Adib S, Cherbuin N, Silva-Monteiro M, Bize P, et al. Partition model based 99mTc-MAA SPECT/CT predictive dosimetry compared to 90Y YOP PET/CT post-treatment dosimetry in radioembolization of hepatocellular carcinoma: A quantitative agreement comparison. J Nucl Med. 2016;57(11):1672–82.

[22] Vinga S, Almeida JS. Renyi continuous entropy of DNA sequences. J Theor Biol 2004;231(3):377–88.

[23] NEMA NU 1-2018: Performance measurements of Gamma Cameras. Virginia; 2019.

[24] Bolch WE, Bouchet LG, Robertson JS, Wessels BW, Siegel JA, Howell RW, et al. MDRO pamphlet No. 17: the dosimetry of nonunit activity distributions-radiocuride S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med. 1999;40(1):11S–36S.

[25] Eckerman KF, Endo AMIRD. Radionuclide Data and Decay Schemes. 2nd ed: Society for Nuclear Medicine; 2008.

[26] Chiesa C, Maccario M, Romito S, Spreafico C, Spoto C, et al. A dosimetric treatment planning strategy in radioembolization of hepatocellular carcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging. 2012;56(6):503–8.

[27] BIPM, IEC. IFCC, IUPAC, IUBMB, IUPHAR, et al. Evaluation of measurement data – Guide to the expression of uncertainty in measurement. Joint Committee for Guides in Metrology (JCGM). 2008.

[28] Gehr J, Cos MG, Gustafsson J, Gleisner KSjgreen, Murray I, Glattting G, et al. EANM practical guidelines on quality assurance for molecular radiotherapy: absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2014;41(13):2456–74.

[29] Du Bois D, Du Bois E. A formula to estimate the approximate surface area for height and body weight known: A practical application. Ann Intern Med 1916;17:863–7.

[30] Gulec SA, Mesoloras G, Dezarn WA, McNeillle P, Kennedy AS. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumour selectivity of the treatment as a function of tumour to liver flow ratio. J Transl Med 2007;5(1). https://doi.org/10.1186/1477-5676-5-15.
[31] Strigari L, Sciuto R, Carpanese L, Pizzi G, Sorisani A, et al. Efficacy and Toxicity Related to Treatment of Hepatocellular Carcinoma with Y-90 SIR Spheres: Radiobiologic Considerations. J Nucl Med. 2010;51(9):1777–85.
[32] Hendlisz A, den Eynde MV, Peeters M, Maleux G, Lambert B, Vannooite J, et al. Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy. J Clin Oncol. 2010;28(23):3687–94.
[33] Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017;18(9):1159–71.
[34] Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): a randomised controlled phase 3 trial. Lancet Oncol 2017;18(12):1624–36.
[35] Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porré P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–68.
[36] Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, et al. Dosimetry Based on Tc-99m-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with Y-90-Loaded Glass Microspheres: Preliminary Results. J Nucl Med. 2012;53(2):255–63.